Drug profile

The FDA adverse-event record for Creatine Ethyl Ester Hcl 400Mg

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Creatine Ethyl Ester Hcl 400Mg. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
30.8%
death-coded share
Dog
most-reported species
6
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
4
Deaths Reported
30.8%
Death Rate

Active Ingredients

Creatine Ethyl Ester Hcl 400Mg

Administration Routes

UnknownOral

Species Affected

Dog 13

Most Affected Breeds

Retriever - Labrador 2
Retriever - Golden 2
Terrier - Yorkshire 2
Schnauzer (unspecified) 1
Mixed (Dog) 1
Maltese 1
Pug 1
Greater Swiss Mountain Dog 1
Dachshund (unspecified) 1
Mastiff 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 6
Anorexia 4
Emesis 3
Elevated alanine aminotransferase (ALT) 3
Death 3
Vomiting 2
Tachycardia 2
Elevated liver enzymes 2
Liver disorder NOS 2
Abnormal ultrasound finding 2
Elevated serum alkaline phosphatase (SAP) 2
Polyuria 1

Outcome Breakdown

Ongoing
6 (46.2%)
Died
3 (23.1%)
Outcome Unknown
2 (15.4%)
Recovered/Normal
1 (7.7%)
Euthanized
1 (7.7%)

Creatine Ethyl Ester Hcl 400Mg Adverse Event Insights

13 reports name Creatine Ethyl Ester Hcl 400Mg; 4 recorded a death outcome (30.8% of reported events, not a population-level mortality rate). Active ingredient: Creatine Ethyl Ester Hcl 400Mg. Administration routes: Unknown, Oral.

By species: Dog (13 reports). By breed: Retriever - Labrador (2), Retriever - Golden (2), Terrier - Yorkshire (2).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (6), Anorexia (4), Emesis (3), Elevated alanine aminotransferase (ALT) (3). Outcome, 13 coded reports: Ongoing leads at 46.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.